Roble, Belko & Company, Inc Recursion Pharmaceuticals, Inc. Transaction History
Roble, Belko & Company, Inc
- $629 Million
- Q4 2024
A detailed history of Roble, Belko & Company, Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 141 shares of RXRX stock, worth $1,022. This represents 0.0% of its overall portfolio holdings.
Number of Shares
141
Previous 16
781.25%
Holding current value
$1,022
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RXRX
# of Institutions
298Shares Held
241MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$238 Million2.05% of portfolio
-
Baillie Gifford & CO24.9MShares$180 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$176 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$125 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$112 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.31B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...